An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children

Bone Marrow Transplantation

Volumn 20, Issue 5, 1997, Pages 347-354

  Chattergoon, D S ^a   Saunders, E F ^a   Klein, J ^a   Calderwood, S ^a   Doyle, J ^a   Freedman, M H ^a   Koren, G ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bone marrow transplantation; Busulphan; Children; Individualised dosing; Limited sampling method; Pharmacokinetics

Indexed keywords

BUSULFAN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COST; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; HURLER SYNDROME; LEUKODYSTROPHY; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0030818478     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700891     Document Type: Article

References (33)

1. Porcellini A, Manna A, Moretti L et al. Busulphan and cyclophosphamide as conditioning regimen for autologous bone marrow transplantation in acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 331-333.
2. Lucarelli G, Galimberti M, Delfini C et al. Marrow transplantation for thalassemia following busulphan and cyclophosphamide. Lancet 1985; 1: 1355-1357.
3. Blazar BR, Ramsay NKC, Kersey JH et al. Pretransplant conditioning with busulphan (myeleran) and cyclophosphamide for nonmalignant diseases. Transplantation 1985; 39; 597-620.
4. Shaw PJ, Hugh-Jones K, Hobbs JR et al. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in 50 children. Bone Marrow Transplant 1986; 1: 193-200.
5. Hobbs JR, Shaw PJ, Hugh-Jones K et al. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in 50 children. Bone Marrow Transplant 1986; 1: 201-208.
6. Brugieres L, Hartmann O, Benhamou E et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumours: incidence, clinical course, and outcome. Bone Marrow Transplant 1988; 3: 53-58.
7. Jones RJ, Lee KSK, Beschorner WE el al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
8. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
9. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with veno-occlusive disease of the liver after bone marrow transplantation. Transplantation 1985; 39: 602-608.
10. Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81: 297-306.
11. Vassal G, Hartmann O, Benhamou E. Busulphan and veno-occlusive disease of the liver. Ann Intern Med 1990; 112: 881.
12. Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
13. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
14. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75; 1723-1727.
15. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chernother Pharmacol 1991; 28: 130-134.
16. 2 the appropriate dose of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
17. Regazzi MB, Locatelli F, Buggia I et al. Disposition of high-dose busulfan in pediatrie patients undergoing bone marrow transplantation. Clin Pharmacol Ther 1992; 53: 45-52.
18. Yeager AM, Wagner JE Jr, Graham ML et al. Optimisation of busulphan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
19. Grochow LB. Busulfan disposition: the role of therapeutic drug monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (Suppl. 4): 18-25.
20. Vassal G, Fischer A, Challine D et al. Busulphan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1034.
21. Schuler U, Schroer S, Kühnle A et al. Busulphan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
22. Haycock GB, Schwanz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. J Paediatr 1978; 93: 62-66.
23. Embree L, Burns RB, Heggie JR et al. Gas-chromatographic analysis of busulphan for therapeutic drug monitoring. Cancer Chemother Pharmacol 1993; 32: 137-142.
24. Ehrsson H, Hassan M. Determination of busulphan in plasma by GC-MS with selected ion monitoring. J Pharmaceut Sci 1983; 72: 1203-1205.
25. Gibaldi M, Perrier D. Pharmacokinetics, Drugs and the Pharmaceutical Sciences, 2nd edn. Marcel Dekker: New York, 1982.
26. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 1979; 9: 115-134.
27. Dawson-Saunders B, Trapp RG (eds). Summarizing data. Basic and Clinical Biostatistics, 2nd edn. Appleton and Lange: Norwalk, CT, USA, 1994, pp 52-53.
28. Dawson-Saunders B, Trapp RG (eds). Estimating and comparing means. Basic and Clinical Biostatistics, 2nd edn. Appleton and Lange: Norwalk. CT, USA, 1994, pp 107-110.
29. Slattery JT, Sanders JE. Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
30. Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-850.
31. Ehninger G, Schuler U, Renner U et al. Use of a water-soluble busulfan formulation. Pharmacokinetic studies in a canine model. Blood 1995; 85: 3247-3249.
32. Hassan M, Ljungman P, Bolme P et al. Busulphan bioavailability. Blood 1994; 84: 2144-2150.
33. Krivit W, Henslee-Downey J, Klemperer M et al. Survival in Hurler's disease following bone marrow transplantation in 84 patients. Bone Marrow Transplant 1995; 15 (Suppl. 1): 182-185.